Venture Partner at Samsara BioCapital · Joined 2022
View Live Interactive Profile →Ravi Rao, Ph.D. joined Samsara BioCapital as a Venture Partner in 2022. The firm states he has been a strategic leader in the research, development, manufacturing or commercialisation activities of five approved drugs (FASENRA, LUMOXITI, ONIVYDE, KEYTRUDA and CYTOGAM) and two biology discovery platforms (ATLAS and TRex Discovery). He served as CEO of TRex Bio, as interim CEO of Complexa, and as Chief Business Officer of Vtesse, where the firm states he led the company from Phase I to a fully enrolled global Phase III within 18 months and was instrumental in the sale of the company. Earlier he held corporate development and strategy consulting roles at Merrimack Pharmaceuticals, Genocea Biosciences, MedImmune/AstraZeneca and Booz & Co. He holds a B.S. in Biology and Chemistry from the University of Wisconsin and a Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania.